Teijin Medical Technologies Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teijin Medical Technologies Co., Ltd.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
SV Health Investors has launched a new $90m venture fund to develop early-stage medtech start-ups. The fund has received investment from Japanese technology group Tejin.
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.
- Medical Devices
- Other Names / Subsidiaries
- Teijin Nakashima Medical Co. Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.